Antiphospholipid Antibodies and Lipids in Hematological Malignancies.

anti-β2 glycoprotein I anticardiolipin antiphospholipid antibodies hematological malignancies lipid lupus anticoagulant

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Apr 2022
Historique:
received: 22 02 2022
revised: 06 04 2022
accepted: 07 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 27 4 2022
Statut: epublish

Résumé

One of the main groups of lipids is phospholipids, which are mainly involved in forming cell membranes. Neoplastic processes such as cell replication have increased lipid synthesis, making tumor cells dependent on this synthesis to maintain their requirements. Antiphospholipid antibodies attack phospholipids in the cell membranes. Three main types of antiphospholipid antibodies are recognized: anti-β2 glycoprotein I (anti-β2GP-I), anticardiolipin (aCL), and lupus anticoagulant (LA). These types of antibodies have been proven to be present in hematological neoplasms, particularly in LH and NHL. This review on antiphospholipid antibodies in hematological neoplasms describes their clinical relationship as future implications at the prognostic level for survival and even treatment.

Identifiants

pubmed: 35456969
pii: ijms23084151
doi: 10.3390/ijms23084151
pmc: PMC9025841
pii:
doi:

Substances chimiques

Antibodies, Anticardiolipin 0
Antibodies, Antiphospholipid 0
Phospholipids 0
beta 2-Glycoprotein I 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Exp Immunol. 2019 Feb;195(2):167-178
pubmed: 30368780
J Crit Care. 2014 Aug;29(4):533-8
pubmed: 24629573
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620928392
pubmed: 32633133
Biochim Biophys Acta. 2012 May;1821(5):754-61
pubmed: 21979151
Med Oncol. 2020 Nov 11;37(12):111
pubmed: 33175248
J Bioenerg Biomembr. 2016 Apr;48(2):99-112
pubmed: 25627476
Clin Exp Immunol. 2018 Aug;193(2):178-182
pubmed: 29645079
Immunol Lett. 2020 May;221:33-38
pubmed: 32092357
J Lipid Res. 2008 Jun;49(6):1187-94
pubmed: 18204095
Biochim Biophys Acta. 2013 Nov;1833(11):2499-510
pubmed: 23711956
J Cancer Res Ther. 2018 Jan;14(1):213-219
pubmed: 29516988
Biochim Biophys Acta. 2014 Jan;1840(1):294-302
pubmed: 24060750
Clin Exp Immunol. 2011 Feb;163(2):189-98
pubmed: 21091668
Autoimmun Rev. 2017 Feb;16(2):173-178
pubmed: 27988438
Curr Med Chem. 2019;26(11):1924-1932
pubmed: 30182838
Hematol J. 2004;5(4):341-6
pubmed: 15297851
Biochim Biophys Acta. 2011 Nov;1811(11):637-47
pubmed: 21704189
Indian J Cancer. 2016 Jan-Mar;53(1):42-3
pubmed: 27146737
Arch Soc Esp Oftalmol. 2017 Feb;92(2):82-85
pubmed: 27268701
Int J Cancer. 2019 May 1;144(9):2074-2081
pubmed: 30125343
Neurocrit Care. 2021 Feb;34(1):227-235
pubmed: 32557110
J Autoimmun. 2018 Aug;92:1-11
pubmed: 29779928
Reumatologia. 2018;56(4):243-248
pubmed: 30237629
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):426-432
pubmed: 31808842
Mol Cancer Ther. 2010 May;9(5):1244-55
pubmed: 20423996
Immunol Res. 2017 Feb;65(1):355-362
pubmed: 27449504
Blood Adv. 2020 Apr 28;4(8):1746-1755
pubmed: 32337583
Mol Immunol. 2013 Mar;53(3):246-54
pubmed: 22964479
Trends Endocrinol Metab. 2018 Feb;29(2):86-98
pubmed: 29203141
Semin Thromb Hemost. 2018 Jul;44(5):483-492
pubmed: 28166601
Sci Rep. 2017 Jun 26;7(1):4243
pubmed: 28652618
Cell Mol Life Sci. 2021 Feb;78(4):1233-1261
pubmed: 33057840
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Nov;1862(11):1325-1339
pubmed: 28007654
Intern Med. 2017;56(10):1207-1212
pubmed: 28502938
Nutrients. 2018 Jun 13;10(6):
pubmed: 29899250
Nat Rev Mol Cell Biol. 2018 May;19(5):281-296
pubmed: 29410529
Dis Model Mech. 2013 Nov;6(6):1353-63
pubmed: 24203995
Immunobiology. 2020 Nov;225(6):152011
pubmed: 33130517
Curr Rheumatol Rep. 2015 Mar;17(3):16
pubmed: 25761923
Blood Rev. 2017 Nov;31(6):406-417
pubmed: 28784423
Clin Rheumatol. 2018 Apr;37(4):875-884
pubmed: 29525845
FEMS Microbiol Rev. 2016 Jan;40(1):133-59
pubmed: 25862689
Lupus. 2020 Sep;29(10):1287-1291
pubmed: 32605525
Crit Rev Oncol Hematol. 2018 Jul;127:42-49
pubmed: 29891110
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
Chin Med J (Engl). 2019 Mar 5;132(5):525-533
pubmed: 30741830
Semin Cancer Biol. 2020 Aug;64:108-113
pubmed: 31351197
BMJ Case Rep. 2019 Mar 14;12(3):
pubmed: 30872333
Thromb Res. 2013;132(6):742-9
pubmed: 24157085
Clin Exp Immunol. 2016 May;184(2):174-82
pubmed: 26702877
Joint Bone Spine. 2017 Jan;84(1):51-57
pubmed: 27118022
Biochem Cell Biol. 2019 Oct;97(5):612-620
pubmed: 30884242
PLoS One. 2012;7(4):e33738
pubmed: 22485149
Environ Health Prev Med. 2018 Oct 20;23(1):50
pubmed: 30340457
Autoimmun Rev. 2016 Dec;15(12):1120-1124
pubmed: 27639837
Sci Rep. 2015 Nov 03;5:15859
pubmed: 26527544
Int J Oncol. 2018 Jan;52(1):5-18
pubmed: 29115416
Chem Rev. 2011 Oct 12;111(10):5817-20
pubmed: 21951202
World Rev Nutr Diet. 2015;112:1-16
pubmed: 25471798
J BUON. 2014 Jan-Mar;19(1):191-7
pubmed: 24659663
World J Gastroenterol. 2020 May 14;26(18):2126-2137
pubmed: 32476780
Int J Mol Sci. 2019 Feb 02;20(3):
pubmed: 30717356
Mol Pharm. 2018 Nov 5;15(11):4777-4800
pubmed: 30226786
Ann Afr Med. 2019 Jul-Sep;18(3):121-126
pubmed: 31417011
J Clin Immunol. 2008 Jul;28(4):291-7
pubmed: 18322784
Lab Med. 2018 Jul 5;49(3):e62-e73
pubmed: 29868860
Allergy Asthma Clin Immunol. 2018 Jun 04;14:24
pubmed: 29881401
Pharmacol Ther. 2017 Sep;177:23-31
pubmed: 28202364
Antibodies (Basel). 2016 Aug 02;5(3):
pubmed: 31557999
Analyst. 2018 Sep 24;143(19):4526-4536
pubmed: 30128447
Nat Rev Dis Primers. 2018 Jan 11;4:17103
pubmed: 29321641
Cardiovasc Diagn Ther. 2020 Oct;10(5):1332-1340
pubmed: 33224757
Intern Emerg Med. 2017 Feb;12(1):1-7
pubmed: 28044251
Eur J Haematol. 2002 Feb;68(2):84-90
pubmed: 12038453

Auteurs

Sonia Guadalupe Barreno-Rocha (SG)

Unidad de Investigación Epidemiológica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico.
Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.

Sandra Guzmán-Silahua (S)

Unidad de Investigación Epidemiológica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico.
Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.

Sinaí-Del-Carmen Rodríguez-Dávila (SD)

Unidad de Investigación Epidemiológica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico.

Guadalupe Estela Gavilanez-Chávez (GE)

Unidad de Investigación Epidemiológica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico.
Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.

Ernesto Germán Cardona-Muñoz (EG)

Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.

Carlos Riebeling-Navarro (C)

Unidad de Investigación en Epidemiologia Clínica, UMAE HP CMN-SXXI, Ciudad de México 06720, Mexico.

Benjamín Rubio-Jurado (B)

Unidad de Investigación Epidemiológica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico.
Departamento Clínico de Hematología, División Onco-Hematologia, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico.

Arnulfo Hernán Nava-Zavala (AH)

Unidad de Investigación Epidemiológica y en Servicios de Salud, CMNO OOAD Jalisco Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico.
Programa Internacional de Medicina, Universidad Autónoma de Guadalajara, Guadalajara 44670, Mexico.
Departamento de Inmunología y Reumatología del Hospital General de Occidente, Secretaría de Salud Jalisco, Guadalajara 45070, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH